Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of

Jyh-Ming, Liou, Chieh-Chang, Chen, Chi-Yang, Chang, Mei-Jyh, Chen, Chien-Chuan, Chen, Yu-Jen, Fang, Ji-Yuh, Lee, Tsung-Hua, Yang, Jiing-Chyuan, Luo, Jeng-Yih, Wu, Tai-Cherng, Liou, Wen-Hsiung, Chang, Yao-Chun, Hsu, Cheng-Hao, Tseng, Chun-Chao, Chang, Ming-Jong, Bair, Tzeng-Ying, Liu, Chun-Fu, Hsieh, Feng-Yun, Tsao, Chia-Tung, Shun, Jaw-Town, Lin, Yi-Chia, Lee, Ming-Shiang, Wu

Significant heterogeneity was observed in previous trials that assessed the efficacies of sequential therapy for 10 days (S10) versus triple therapy for 14 days (T14) in the first-line treatment ofWe conducted this open-label randomised multicentre trial in eight hospitals and one community in Taiwan. 1300 adult subjects withThe eradication rates of S10 and T14 were 87.2% (567/650, 95% CI 84.4% to 89.6%) and 85.7% (557/650, 95% CI 82.8% to 88.2%) in the ITT analysis, respectively, and were 91.6% (556/607, 95% CI 89.1% to 93.4%) and 91.0% (548/602, 95% CI 88.5% to 93.1%) in the PP analysis, respectively. There were no differences in compliance or adverse effects. The eradication rates in strains susceptible and resistant to clarithromycin were 90.7% and 62.2%, respectively, for S10, and were 91.5% and 44.4%, respectively, for T14. The efficacy of T14, but not S10, was affected by CYP2C19 polymorphism.S10 was not superior to T14 in areas with low clarithromycin resistance.NCT01607918.

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of

この論文をさがす

説明

収録刊行物

キーワード

詳細情報詳細情報について

書き出し

問題の指摘